CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05257590
• Other study ID #: CVM-008
• Status: Recruiting
• Phase: Phase 2
• Start date: May 23, 2022
• Est. completion date: March 31, 2026

Study information

• Verified date: July 2023
• Source: TaiRx, Inc.
• Contact: Yen-Ling Chen, PhD
• Phone: 886-2-2653-5007
• Email: yenlingchen[@]trx.com.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.

Description:

Nivolumab, a human IgG4 kappa monoclonal antibody acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2 ) and therefore preventing the activation of T cells from attacking the cancer. Nivolumab is currently approved for several cancer types.

To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 can promote apoptosis and delay proliferation. Moreover, CVM-1118 targets the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib or bevacizumab. Hence, the ability of inhibiting the VM network makes CVM-1118 a potential good combination drug with Nivolumab in advanced diseases such as hepatoma where Nivolumab alone has shown activity.

The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential drug-drug interactions of CVM-1118 and Nivolumab are very low.

Based on the mechanism of actions and the safety analysis of nivolumab and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with unresectable advanced HCC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 95
• Est. completion date: March 31, 2026
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18+ (20+ for subjects in Taiwan)

• Diagnosis of hepatocellular carcinoma

• Pathologically or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) criteria (i.e., radiologic imaging with cross-sectional multiphasic contrast CT or MRI showing a = 1 cm liver lesion)

• Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).

• Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C

• Child-Pugh liver function class A

• Measurable disease (per mRECIST)

• ECOG performance status of 0 to 1

• Adequate laboratory parameters including:

• AST and ALT = 3.0 x ULN (= 5.0 x ULN if due to liver involvement)

• Total serum bilirubin = 2.0 x ULN (= 3.0 x ULN for subjects with documented Gilbert's syndrome)

• ANC =1500/µL

• Platelets = 90,000/µL

• HGB = 9.0 g/dL

• Serum creatinine clearance of = 50 mL/min based on Cockcroft-Gault formula

• Serum albumin = 2.8 gm/dL

• INR = 2.3

• PT/aPTT = 1.2 x ULN

• QTcF = 480 msec

• Subjects are eligible to enroll if they have HBV-, or HCV-HCC, defined as follows:

• Chronic HBV infection as evidenced by detectable HBV DNA or HBsAg. Subjects with chronic HBV infection must be on antiviral therapy and have HBV DNA <500 IU/mL. If not on an antiviral therapy at screening, then subjects must be willing to start the antiviral therapy at the time of consent.

• Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.

Exclusion Criteria:

• HCC with portal vein invasion at the main portal branch (Vp4)

• Known history of esophageal varices or gastrointestinal bleeding within the past 3 months

• Prior immunotherapy for hepatoma

• = 7 days from prior limited field palliative irradiation therapy and C1D1

• = 28 days from prior irradiation therapy and C1D1

• = 14 days (or 5 half-lives) from prior systemic anticancer therapy and C1D1

• = 28 days from local regional therapy (e.g., trans-arterial embolization, radiofrequency ablation) and C1D1

• Presence of other active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints

• Active bacterial or fungal infection(s) requiring systemic therapy within 7 days prior to C1D1

• Known CNS metastases

• Known history of HIV infection

• Females who are currently pregnant or breast-feeding

• Known gastrointestinal disease that may significantly alter the absorption of oral medications

• Psychiatric illness or social situation that would interfere with compliance with study requirements

• History of clinically significant cardiovascular abnormalities

Related Conditions & MeSH terms

• Advanced Cancer
• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Drug:
• Nivolumab Injection [Opdivo]
Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
• CVM-1118
CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.

Locations

Country	Name	City	State
Taiwan	Kaohsiung Chang Gung Memorial Hospital	Kaohsiung
Taiwan	Keelung Chang Gung Memorial Hospital	Keelung
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
TaiRx, Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)_mRECIST	Assessment by modified RECIST criteria	24 weeks after the last subject starts CVM-1118
Secondary	Objective Response Rate (ORR)_RECIST v1.1	Assessment by RECIST v1.1 criteria	24 weeks after the last subject starts CVM-1118
Secondary	Duration of response (DoR)	Duration of response (DoR) is defined as time from the first documentation of response to the time of progression	24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Secondary	Progression free survival (PFS)	Progression free survival (PFS) is defined as time from the first dose of study drug to the time of progression or death	24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Secondary	Overall survival (OS)	Overall survival (OS) is defined as time from first dose of study drug to death	24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Secondary	Time to progression (TTP)	Time to progression (TTP) is defined as the time from the first dose of study drug to the time of progression	24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose
Secondary	Disease control rate (DCR)	Disease control rate (DCR) is defined as the sum of complete response (CR), partial response (PR), and stable disease rate (SD)	24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose
Secondary	Rate of Adverse event (AE) and Serious Adverse Event (SAE)	Rate of Adverse event (AE) and Serious Adverse Event (SAE) are assessed using Common Terminology Criteria for Adverse Events v.5 (CTCAE) criteria	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.
Secondary	Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ body temperature by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure (both systolic and diastolic blood pressure) by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ Heart rate by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v5	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Number of patients with abnormalities in electrocardiography (ECG) reporting for PR, QRS, QT, and QTcF intervals	Values with CTCAE v5 Grade ? 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.	Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment
Secondary	Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing	Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 will be measured to see maximum exposure after CVM-1118 dosing	During Cycle 1 and Cycle 2 (each cycle is 28 days)
Secondary	Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing	Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing	During Cycle 1 and Cycle 2 (each cycle is 28 days)
Secondary	Pharmacodynamics analysis for the relationship of Cmax and ORR	Relationship between Cmax and ORR will be evaluated	During Cycle 1 and Cycle 2 (each cycle is 28 days)
Secondary	Pharmacodynamics analysis for the relationship of AUC and ORR	Relationship between AUC and ORR will be evaluated	During Cycle 1 and Cycle 2 (each cycle is 28 days)
Secondary	Pharmacodynamics analysis for the relationship of Cmax and AE	Relationship between Cmax and AE will be evaluated	During Cycle 1 and Cycle 2 (each cycle is 28 days)
Secondary	Pharmacodynamics analysis for the relationship of AUC and AE	Relationship between AUC and AE will be evaluated	During Cycle 1 and Cycle 2 (each cycle is 28 days)